LUCENTIS™ (ranibizumab injection) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF‑A).
LUCENTIS is indicated for the treatment of patients with neovascular (wet) age‑related macular degeneration.
Media Articles Related to Lucentis (Ranibizumab)
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2016.05.06]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 12:00:00 AM
Last Editorial Review: 5/6/2016 12:00:00 AM
'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010
Are Oral Bisphosphonates Associated With Wet AMD?
Source: Medscape Ophthalmology Headlines [2016.09.23]
With the rising prevalence of oral bisphosphonate use and wet age-related macular degeneration, we must ask ourselves if the two are related.
Gene therapy in a droplet could treat eye diseases, prevent blindness
Source: Eye Health / Blindness News From Medical News Today [2016.07.28]
Eye diseases such as diabetic retinopathy and age-related macular degeneration are among the leading causes of irreversible vision loss and blindness worldwide.
Published Studies Related to Lucentis (Ranibizumab)
Randomized clinical trial evaluating intravitreal ranibizumab or saline for
vitreous hemorrhage from proliferative diabetic retinopathy. 
IMPORTANCE: Vascular endothelial growth factor plays a role in proliferative
diabetic retinopathy (PDR). Intravitreal injection of saline has been shown
potentially to lead to improved visual acuity compared with observation alone in
eyes with vitreous hemorrhage...
Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011.12]
OBJECTIVE: To explore the association between treatment for neovascular age-related macular degeneration (AMD) and incidence and timing of retinal pigment epithelium (RPE) tears in ranibizumab-treated patients versus control treatment. DESIGN: Results from 3 phase III clinical trials (ANti-VEGF antibody for the treatment of predominantly classic CHORoidal neovascularization in age-related macular degeneration [ANCHOR], Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-related macular degeneration [MARINA], and A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization [CNV] with or without Classic CNV Secondary to Age-Related Macular Degeneration [PIER]) were retrospectively reviewed to identify patients who developed RPE tears during the study period, detected on fluorescein angiography performed at prespecified intervals. PARTICIPANTS: Patients with baseline and post-baseline angiographic assessments... CONCLUSIONS: As studied in these trials, no statistically significant differences in the incidence of RPE tears within a 2-year treatment period were observed in patients who received ranibizumab (0.5 or 0.3 mg) versus control treatment, although most RPE tears with ranibizumab occurred within 3 months of initiating treatment. Mean VA was better in patients who developed RPE tears while receiving ranibizumab than in those who received control treatment, suggesting a potential benefit of continued ranibizumab therapy in patients with neovascular AMD who developed RPE tears. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. [2011.10]
PURPOSE: Assess the 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO). DESIGN: Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial. PARTICIPANTS: We included 392 patients with macular edema after CRVO... CONCLUSIONS: On average, treatment with ranibizumab as needed during months 6 through 11 maintained the visual and anatomic benefits achieved by 6 monthly ranibizumab injections in patients with macular edema after CRVO, with low rates of ocular and nonocular safety events. After sham injections for 6 months, treatment with ranibizumab as needed for 6 months resulted in rapid reduction in CFT in the sham/0.5 mg group to a level similar to that in the 2 ranibizumab treatment groups and an improvement in BCVA, but not to the same level as that in the 2 ranibizumab groups. Intraocular injections of ranibizumab provide an effective treatment for macular edema after CRVO. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. [2011.08.20]
PURPOSE:: To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone... CONCLUSION:: This pilot study is the first to prospectively identify a biologic signal that may indicate combination therapy with an easily administered well-tolerated eyedrop and ranibizumab is efficacious for the treatment of neovascular age-related macular degeneration. Further studies are warranted to validate this finding.
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. [2011.08]
PURPOSE: Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO). DESIGN: Prospective, randomized, sham injection-controlled, double-masked, multicenter trial. PARTICIPANTS: A total of 397 patients with macular edema after BRVO... CONCLUSIONS: At month 12, treatment with ranibizumab as needed during months 6-11 maintained, on average, the benefits achieved by 6 monthly ranibizumab injections in patients with macular edema after BRVO, with low rates of ocular and nonocular safety events. In the sham/0.5 mg group, treatment with ranibizumab as needed for 6 months resulted in rapid reduction in CFT to a similar level as that in the 0.3 mg ranibizumab treatment group and an improvement in BCVA, but not to the extent of that in the 2 ranibizumab groups. Intraocular injections of ranibizumab provide an effective treatment for macular edema after BRVO. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Lucentis (Ranibizumab)
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration [Completed]
Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration [Active, not recruiting]
The aim of this study is to test if PF582 (ranibizumab) is safe and similar to Lucentis
(ranibizumab). Participants will have a screening visit to check for eligibility. Eligible
participants will receive either PF582 or Lucentis, by injection into one eye on study Day
1, 28 and 56. Visits will be conducted on Day 2, 7, 14 80 and at 6 and 12 months. During the
study participants will undergo the following procedures: height, weight and vital signs
(blood pressure, pulse, temperature, breathing rate) measurement; medical and surgical
history and concomitant medications; adverse event monitoring; physical examinations; eye
tests (reading chart, measurement of retinal thickness [via pictures of the retina] and
examination of the eye's blood vessels, via pictures taken following injection of a dye into
the arm), blood collection and a urine pregnancy test, where applicable.
Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma [Completed]
This is a Phase I clinical trial to test the safety and tolerability of intravitreal
ranibizumab in the treatment of radiation retinopathy following plaque brachytherapy for
patients with choroidal melanoma using the incidence and severity of events criteria.
The secondary objective is to assess the efficacy of intravitreal ranibizumab on regression
of radiation retinopathy by ophthalmic examination, fundus photography, fluorescein
angiography, and optical coherence tomography, as well as visual acuity.
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy [Completed]
This Phase I/II safety study is designed to investigate the safety and efficacy of
ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a
potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels
under the retina. These abnormal blood vessels can bleed or leak fluid, causing disruption
of normal retinal function and vision loss. Ranibizumab is a drug that is FDA-approved for
the treatment of wet age-related macular degeneration (AMD) and is injected directly into
the eye. Given the efficacy of ranibizumab in the treatment of wet AMD, and the postulated
similarity between the disease mechanisms involved in both wet AMD and PCV, we believe
ranibizumab will have a beneficial effect on visual function in patients with PCV.
Ranibizumab for the Inhibition of Neovascularization in Pterygia [Completed]
Reports of Suspected Lucentis (Ranibizumab) Side Effects
Visual Acuity Reduced (192),
Cerebrovascular Accident (153),
Myocardial Infarction (119),
Drug Ineffective (101),
Visual Impairment (64),
Eye Haemorrhage (61),
Retinal Haemorrhage (61),
Malaise (60), more >>
Page last updated: 2016-09-23